Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Self-associated Indisulam In Phospholipid-based Nanomicelles: A Potential Nanomedicine For Cancer.

H. Cesur, I. Rubinstein, A. Pai, H. Onyüksel
Published 2009 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This study aimed to begin development of a nanomedicine containing indisulam solubilized in sterically stabilized micelles (SSMs) composed of DSPE-PEG(2000) or sterically stabilized mixed micelles (SSMMs) composed of DSPE-PEG(2000) plus egg phosphatidylcholine. Micelles were prepared by co-precipitation and reconstitution of drug and lipids. Particle size distributions of micellar formulations were determined by quasi-elastic light scattering. Amounts of solubilized drug were determined by reverse-phase high-performance liquid chromatography (RP-HPLC). In vitro cytotoxicity of indisulam in nanocarrier was determined on the MCF-7 cell line by the National Cancer Institute-developed sulforhodamine B assay. Optimal solubilized indisulam concentrations in 5 mM total lipid were 10 microg/mL for SSMMs and 400 microg/mL for SSMs. HPLC results demonstrated that the encapsulation capacity of both micelles was over 95%. In vitro studies showed that indisulam in micellar system was more effective than free indisulam. The optimized formulation was successfully freeze-dried without any addition of lyoprotectants or cryoprotectants. We conclude that SSMs are a promising nanocarrier for indisulam, and indisulam-SSMs should be developed further as a novel targeted nanomedicine.
This paper references
10.1023/A:1012287111922
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
C. Punt (2001)
10.1016/J.ADDR.2004.01.011
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
A. Gabizon (2004)
10.1634/THEONCOLOGIST.12-4-375
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
D. Tripathy (2007)
Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis.
A. Yokoi (2002)
10.1016/S0022-1759(97)00137-3
Optimization of the sulforhodamine B colorimetric assay.
K. Papazisis (1997)
10.1038/nprot.2006.179
Sulforhodamine B colorimetric assay for cytotoxicity screening
V. Vichai (2006)
10.3109/9781420017267
Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs
J. Dressman (2007)
10.1200/JCO.2002.09.030
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
E. Raymond (2002)
10.1124/dmd.105.008326
SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES
A. Zandvliet (2006)
10.1023/A:1020488012264
Polyethylene Glycol-Diacyllipid Micelles Demonstrate Increased Accumulation in Subcutaneous Tumors in Mice
A. Lukyanov (2004)
10.1002/JPS.20150
In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation.
B. Ashok (2004)
10.1023/A:1022243709003
Sterically Stabilized Phospholipid Mixed Micelles: In Vitro Evaluation as a Novel Carrier for Water-Insoluble Drugs
A. Krishnadas (2004)
10.1016/J.BMCL.2003.09.062
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.
F. Abbate (2004)
10.1023/A:1010608317361
Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells
K. Fukuoka (2004)
10.1111/j.1349-7006.2005.00109.x
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
Y. Yamada (2005)
10.1201/9781315114361-15
Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
O. Koo (2005)
10.1038/sj.bjc.6603606
A phase I and pharmacokinetic study of indisulam in combination with carboplatin
C. Dittrich (2007)
10.1081/DDC-100102190
Solubility and stability of lorazepam in bile salt/soya phosphatidylcholine-mixed micelles.
M. A. Hammad (1999)
10.1016/j.ijpharm.2008.01.014
Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles.
S. B. Lim (2008)
10.1023/A:1018847501985
A Novel Formulation of VIP in Sterically Stabilized Micelles Amplifies Vasodilation In Vivo
H. Önyüksel (2004)
10.1016/S0168-3659(02)00442-X
Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives.
J. X. Zhang (2003)
10.1093/ANNONC/MDI016
Phase II study of E7070 in patients with metastatic melanoma.
J. F. Smyth (2005)
10.1016/J.NANO.2005.06.004
Role of nanotechnology in targeted drug delivery and imaging: a concise review.
O. Koo (2005)
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a onehour infusion every three weeks in patients with advanced cancer
E Raymond (2002)
a concise review
OM Koo (2009)
10.1016/S0959-8049(01)00275-1
E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.
Y. Ozawa (2001)
10.1021/JM9902638
Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.
T. Owa (1999)
10.1016/J.ADDR.2003.12.004
Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.
A. Lukyanov (2004)
10.1158/1535-7163.MCT-04-0234
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays
N. Nakatsu (2005)



This paper is referenced by
10.1016/j.ijpharm.2019.118586
Improved self-assembled micelles based on supercritical fluid technology as a novel oral delivery system for enhancing germacrone oral bioavailability.
Xuefeng Hou (2019)
10.2147/IJN.S25363
Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations
M. Sahib (2011)
10.1201/B11076-17
Phospholipid-based Nanomicelles in Cancer Nanomedicine
H. Onyuksel (2011)
10.1016/j.nano.2015.02.016
Intestinal absorption of fluorescently labeled nanoparticles.
S. Simović (2015)
10.2147/IJN.S118568
Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer
Y. Gu (2016)
10.1016/j.apsb.2019.07.003
Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats
Wen-hao Li (2020)
10.1201/B10846-10
Transmucosal and Ocular Drug Delivery
Vasant V. Ranade (2011)
10.1016/j.ijpharm.2016.02.019
Lipid-based nanoformulations for peptide delivery.
N. Matougui (2016)
10.1016/j.biomaterials.2011.01.038
The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery.
Hongjuan Yao (2011)
10.1208/s12249-014-0146-3
A New Lipid-Based Nano Formulation of Vinorelbine
F. Bahadori (2014)
10.1007/s11095-016-2021-2
A pH-Sensitive Nanocarrier for Tumor Targeting
Ligang Chen (2016)
10.1016/j.msec.2017.02.048
Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride.
Baomei Zhang (2017)
10.1016/j.jconrel.2017.06.019
Self‐assembled amphiphilic core‐shell nanocarriers in line with the modern strategies for brain delivery
Reham S. Elezaby (2017)
10.1016/B978-0-12-391860-4.00018-5
Nanomedicines for inflammatory diseases.
Fatima Khaja (2012)
Formulation and Characterization of Phospholipid Based Micelles: A Potential Carrier for Cancer
Mayank Chaudhari (2019)
A novel antineoplastic nano-lipobubble drug delivery system for passively targeted ovarian cancer therapy
Derusha Frank (2015)
10.1081/E-EBPPC-120050073
Nanoparticles: Cancer Management Applications
Shyamasree Ghosh (2017)
10.1016/B978-0-444-52824-7.00009-3
Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation
C. Avendaño (2008)
Developing health service delivery in a poor and marginalised community in North West Pakistan
Rajneet Kaur Khurana (2019)
10.1016/B978-0-444-62649-3.00010-7
Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation: Kinase Inhibitors
C. Avendaño (2015)
10.1021/acsami.9b04051
pH-Responsive Nanoparticles Targeted to Lungs for Improved Therapy of Acute Lung Inflammation/Injury.
C. Zhang (2019)
10.1002/wnan.1185
Peptide delivery using phospholipid micelles.
A. Banerjee (2012)
10.1016/j.jconrel.2012.06.002
Improvement of drug safety by the use of lipid-based nanocarriers.
S. B. Lim (2012)
10.1007/978-3-319-11728-7_9
Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting
S. Ghosh (2015)
10.1002/ddr.21000
Incorporation of Beclomethasone Dipropionate into Polyethylene Glycol‐Diacyl Lipid Micelles as a Pulmonary Delivery System
Mohanad Naji Sahib (2012)
A Novel Anti-Diabetic Peptide Nanomedicine Against Pancreatogenic Diabetes
Amrita Banerjee (2012)
10.1016/j.bbrc.2018.01.042
Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer.
Nana Han (2018)
10.1007/s10989-012-9292-1
Sterically Stabilized Phospholipid Micelles Reduce Activity of a Candidate Antimicrobial Wound Healing Adjunct
R. Williams (2012)
10.1007/s13346-012-0107-x
VIP-targeted cytotoxic nanomedicine for breast cancer
Aparna Dagar (2012)
10.1201/B11076-17
Radiation Protection with Nanoparticles
C. Baker (2011)
10.1007/s40011-012-0080-7
Drug Delivery Using Nanocarriers: Indian Perspective
S. Gupta (2012)
10.1002/jps.24193
Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.
Nilesh I. Gupta (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar